NCT05407675 2025-10-03A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid TumorsBristol-Myers SquibbPhase 1/2 Completed68 enrolled 27 charts